ClinicalTrials.gg
CompletedNCT03194555Updated Apr 10, 2024Results posted

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

A Phase 2 interventional study of Low-Dose Naltrexone and Acetaminophen Combination and Placebo in Migraine With or Without Aura, sponsored by Allodynic Therapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-10.

Sponsored by Allodynic Therapeutics, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing acetaminophen in Headache — 1 open to participants now, 1 under way, 1 of them phase 3. Acetaminophen · Headache.

Enrollment
10th of 11
12 · median 80
Started
2017
with 1 other
Phase 2
Only one
of the 11
Registered
7th of 11
by date
Lead sponsor
1 of 11
Allodynic Therapeutics, Inc

Among the 11 studies testing acetaminophen in Headache, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is the only one in phase 2, and was the 7th registered.

Headache

762 studies on the registry are indexed under Headache; 134 are open to participants now.

Browse Headache studies →

Open to participants now

1 of the 11 studies testing acetaminophen in Headache is open now. Recruiting first, the newest first:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing acetaminophen in Headache, or all of them as a file.
02

Study summary

The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders

03

Conditions studied

  • Migraine With or Without Aura

Keywords

  • Innate Immune System
  • Cytokines
  • Cox-2
  • Headache
  • Migraine
  • Migraine Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is a male or a female 18 years of age or older.
  2. History of migraine with or without aura according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with onset of migraine prior to 50 years of age.
  3. Migraine-associated nausea with ≥half of migraine attacks.
  4. 5-8 migraine/probable migraine headache days on average per month in the three months prior to Visit 1 and during the Baseline Period.
  5. The patient agrees to refrain from taking opiate medications from Visit 1 to 7 days after the last dose of the study drug.
  6. The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written and authorize HIPAA.
  7. The patient has been taking a stable dose of a medication with migraine prevention potential for at least 3 month prior to the screening visit and agrees to not start, stop, or change dosage of any medication with migraine prevention potential during the study period. (E.g., beta-blockers, calcium channel blockers, tricyclic antidepressants, anticonvulsants, selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine re-uptake inhibitors (SNRIs), magnesium or riboflavin supplements at high doses, herbal preparations (e.g. feverfew or St. john's wort)), Botulinum toxin must be discontinued one year prior to Visit 1.
  8. The patient agrees to forgo any elective surgery for the duration of the study.
  9. The female patient who is premenopausal or less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit to using 2 methods of adequate and reliable throughout the study and for 28 days after taking the last dose of the study drug (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). Male patients must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after the study.

Exclusion criteria

Exclusion Criteria:

  1. Usage of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) ≥15 days/month, or ergotamine and triptans >10 days/month, or opioids and barbiturates >2 days/month in the 3 months prior to Visit 1 or during the Baseline Period.
  2. Tension-type-like, and/or migraine-like headache on ≥15 days per month in the 3 months prior to Visit 1 or during the Baseline Period. Diagnosis of chronic migraine, cluster headache or neurologically complicated migraine (hemiplegic, basilar, retinal, ophthalmoplegic migraine).
  3. Regular use of the following medications for any reason: acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), antipsychotic drugs, monoamine oxidase inhibitors, benzodiazepines, sleep medications, muscle relaxants, anti-emetic medications, blood thinning medications (e.g., warfarin or heparin), cannabinoids, or botulinum toxin to head and neck regions. Low-dose aspirin for cardiovascular disease prophylaxis is permitted.
  4. Confounding painful conditions, (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome, etc.).
  5. Diagnosis of any concurrent medical or psychiatric condition; this includes, chronic unstable debilitating diseases such as Parkinson's disease, multiple sclerosis, cancer, significant renal impairment, significant hepatic impairment, etc.
  6. The patient has a history or diagnosis of moderate-to-severe hepatic or renal impairment (>2 × the [ULN] for or aspartate transaminase. ≥1.5 × ULN for alkaline Phosphatase, , BUN, or creatinine). (Patients with elevated bilirubin level due to Gilbert's syndrome are allowed).
  7. The patient has a history within the previous 5 years of abuse of any drug, prescription, illicit, or alcohol.
  8. The Female patient is pregnant, actively trying to become pregnant, or breast-feeding. The Male patient is not practicing 2 different methods of with their partner during the study, and for 28 days after the drug last dose or will not remain abstinent during the study, and for 28 days after the last dose.
  9. The patient has known-allergy to any of the components of the investigational drug.
  10. Participation in another study with an investigational drug within 30 days before Visit 1 or during the study.
  11. Use of emergency care treatment more than 3 times in the previous 6 months.
  12. The patient is in the opinion of the investigator, is unsuitable to participate in this study for any other reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Low-Dose Naltrexone and Acetaminophen Combination

    Drug: Low-Dose Naltrexone and Acetaminophen Combination

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugLow-Dose Naltrexone and Acetaminophen Combination

    Drug pages: Naltrexone · Acetaminophen

    Twice daily

  • DrugPlacebo

    Twice daily

06

What researchers measure

Primary outcomes

  1. Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period.

    Migraine with or without aura is defined according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version). Migraine headaches must be moderate or severe and lasting ≥30 minutes. When the patient falls asleep during migraine and wakes up without it, duration of the attack is reckoned until the time of awakening).

    Time frame: From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.

Secondary outcomes

  1. The Number of Participants With More Than 50% Improvement in the Mean Monthly Migraine Days (MMDs)

    MMD stands for change in Monthly Migraine Days from 28-day baseline to the last 28 days of the double-blind treatment period

    Time frame: From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.

  2. The Number of Participants With More Than 75% Improvement in the Mean Monthly Migraine Days (MMDs)

    Time frame: From the28-day baseline period to the last 28 days of the 84-day treatment period.

  3. The Number of Participants With 100% Improvement in Mean MMD in the Last 28 Days Double-blinded Treatment Period.

    Time frame: From the 28-day baseline period to the last 28 days of the 84-day treatment period.

  4. Mean Monthly Acute Migraine Medication Treatment Days Change From Baseline to Last 28 Days of Treatment

    Time frame: From the 28-day baseline period to the last 28 days of the 84-day treatment period.

  5. The Change in HIT-6 From Baseline to Last 28 Days of Treatment

    HIT-6 - headache impact test - was designed to provide a global measure of adverse headache impact. Score range is 36-78, Score ≥ 60 - a very severe impact on life, scored ≤ 49 little to no impact on life. The percent responders were calculated as follows: the change from baseline score divided by the score at the baseline minus 36.

    Time frame: From the 28-day baseline period to the last 28 days of the 84-day treatment period.

Other outcomes

  1. The Change in Mean PIRS-20 From Baseline to Last 7 Days of Treatment.

    Average of PIRS-20, (0-60 = higher with difficulty with sleep)

    Time frame: From baseline to month 3 of the treatment period.

  2. The Number of Participants Who Had an Improvement in Patient Global Impression of Change (PGIC) at End of Treatment

    Time frame: From baseline to month 3 of the treatment period.

  3. The Number of Participants Reporting Patients' Satisfaction Level

    Time frame: From baseline to month 3 of the treatment period.

  4. Mean Monthly Migraine Hours Change From Baseline to Last 28 Days of Treatment

    Time frame: From baseline to month 3 of the treatment period.

  5. Change in at Least Moderate Migraine Days in Treatment

    Time frame: From baseline to month 3 of the treatment period

  6. The Number of Participants Who Achieved the Percentage of Response in at Least Moderate Migraine Days Baseline to Last 28 Days of Treatment

    Time frame: From baseline to month 3 of the treatment period.

  7. Mean Severe Headache Days Change From Baseline to Last 28 Days of Treatment

    Time frame: From baseline to month 3 of the treatment period.

07

Results

Posted Apr 10, 2024

Participant flow

Patient recruitment was conducted in a single site in Miami, Florida.

Participant flow — Overall Study
MilestoneLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Started66
Completed66
Not completed00

Outcome measures

PrimaryChange in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period.

Migraine with or without aura is defined according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version). Migraine headaches must be moderate or severe and lasting ≥30 minutes. When the patient falls asleep during migraine and wakes up without it, duration of the attack is reckoned until the time of awakening).

Time frame:
From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.
Reported as:
Mean · days
Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period.
daysLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period.-5.67 ± 3.2-3.5 ± 5.56
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.4267 · Risk difference (rd): -2.17 · 95% CI -3.67 to 8.01
SecondaryThe Number of Participants With More Than 50% Improvement in the Mean Monthly Migraine Days (MMDs)

MMD stands for change in Monthly Migraine Days from 28-day baseline to the last 28 days of the double-blind treatment period

Time frame:
From the 28-day baseline period to the last 28 days of the 84-days double-blinded treatment period.
Reported as:
Count of participants · Participants
The Number of Participants With More Than 50% Improvement in the Mean Monthly Migraine Days (MMDs)
ParticipantsLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
The Number of Participants With More Than 50% Improvement in the Mean Monthly Migraine Days (MMDs)42
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.268 · Risk difference (rd): 2 · 95% CI -18.46 to 66.83
SecondaryThe Number of Participants With More Than 75% Improvement in the Mean Monthly Migraine Days (MMDs)
Time frame:
From the28-day baseline period to the last 28 days of the 84-day treatment period.
Reported as:
Count of participants · Participants
The Number of Participants With More Than 75% Improvement in the Mean Monthly Migraine Days (MMDs)
ParticipantsLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
The Number of Participants With More Than 75% Improvement in the Mean Monthly Migraine Days (MMDs)41
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.0926 · Risk difference (rd): 3 · 95% CI -17.2 to 67.4
SecondaryThe Number of Participants With 100% Improvement in Mean MMD in the Last 28 Days Double-blinded Treatment Period.
Time frame:
From the 28-day baseline period to the last 28 days of the 84-day treatment period.
Reported as:
Count of participants · Participants
The Number of Participants With 100% Improvement in Mean MMD in the Last 28 Days Double-blinded Treatment Period.
ParticipantsLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
The Number of Participants With 100% Improvement in Mean MMD in the Last 28 Days Double-blinded Treatment Period.31
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.2894 · Risk difference (rd): 2 · 95% CI -17.2 to 67.4
SecondaryMean Monthly Acute Migraine Medication Treatment Days Change From Baseline to Last 28 Days of Treatment
Time frame:
From the 28-day baseline period to the last 28 days of the 84-day treatment period.
Reported as:
Mean · days
Mean Monthly Acute Migraine Medication Treatment Days Change From Baseline to Last 28 Days of Treatment
daysLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Baseline acute number of migraine medication treatment days7.67 ± 2.078.67 ± 3.5
Acute migraine medication treatment days in last 28 days of treatment period2.67 ± 4.325.5 ± 3.27
change in monthly acute migraine medication treatment days baseline to last 28 days of treatment-5 ± 5.37-3.17 ± 5.49
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.5724 · Risk difference (rd): -1.83 · 95% CI -5.1557 to 8.8157
SecondaryThe Change in HIT-6 From Baseline to Last 28 Days of Treatment

HIT-6 - headache impact test - was designed to provide a global measure of adverse headache impact. Score range is 36-78, Score ≥ 60 - a very severe impact on life, scored ≤ 49 little to no impact on life. The percent responders were calculated as follows: the change from baseline score divided by the score at the baseline minus 36.

Time frame:
From the 28-day baseline period to the last 28 days of the 84-day treatment period.
Reported as:
Mean · score
The Change in HIT-6 From Baseline to Last 28 Days of Treatment
scoreLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Baseline (Randomization visit) mean HIT-6, score68.5 ± 5.6868.83 ± 5.27
HIT-6 in last 28 days of treatment, score47.83 ± 17.6958 ± 12.08
The change in HIT-6 from baseline to last 28 days of treatment, score-20.67 ± 19.08-10.83 ± 12.98
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.2998 · Risk difference (rd): -9.84 · 95% CI -11.15 to 30.83
Other pre-specifiedThe Change in Mean PIRS-20 From Baseline to Last 7 Days of Treatment.

Average of PIRS-20, (0-60 = higher with difficulty with sleep)

Time frame:
From baseline to month 3 of the treatment period.
Reported as:
Mean · score
The Change in Mean PIRS-20 From Baseline to Last 7 Days of Treatment.
scoreLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Baseline (Randomization visit) mean PIRS-20, score32.67 ± 16.9731.83 ± 7.03
PIRS-20 in last week of treatment period, score10 ± 19.3220.83 ± 14.39
The change in PIRS-20 from baseline to last week of treatment, score-22.67 ± 22.64-11 ± 8.92
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.2673 · Risk difference (rd): -11.67
Other pre-specifiedThe Number of Participants Who Had an Improvement in Patient Global Impression of Change (PGIC) at End of Treatment
Time frame:
From baseline to month 3 of the treatment period.
Reported as:
Count of participants · Participants
The Number of Participants Who Had an Improvement in Patient Global Impression of Change (PGIC) at End of Treatment
ParticipantsLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
PGIC, Change≥2 points, (%)42
PGIC, Change=3 points, (%)42
Other pre-specifiedThe Number of Participants Reporting Patients' Satisfaction Level
Time frame:
From baseline to month 3 of the treatment period.
Reported as:
Count of participants · Participants
The Number of Participants Reporting Patients' Satisfaction Level
ParticipantsLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Satisfied or very satisfied (level 2 or 3)42
Very satisfied (level 3)42
Other pre-specifiedMean Monthly Migraine Hours Change From Baseline to Last 28 Days of Treatment
Time frame:
From baseline to month 3 of the treatment period.
Reported as:
Mean · Hours
Mean Monthly Migraine Hours Change From Baseline to Last 28 Days of Treatment
HoursLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Baseline, hours70.78 ± 47.654.44 ± 36.21
Monthly migraine hours in last 28 days of treatment, hours24.65 ± 35.2337.07 ± 38.05
The change in monthly migraine hours from baseline to last 28 days of treatment, hours-46.13 ± 59.44-17.37 ± 41.11
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.3527 · Risk difference (rd): 28.76 · 95% CI -94.5005 to 36.9805
Other pre-specifiedChange in at Least Moderate Migraine Days in Treatment
Time frame:
From baseline to month 3 of the treatment period
Reported as:
Mean · days
Change in at Least Moderate Migraine Days in Treatment
daysLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Mean monthly at least moderate Headaches days at baseline8.33 ± 2.739 ± 2.45
Mean at least moderate migraine days in the last 28 days of the treatment period3.67 ± 5.576.17 ± 4.54
The change in at least moderate migraine days from baseline to the last 28 days of treatment period-4.78 ± 4.42-2.83 ± 5.74
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.5246 · Risk difference (rd): -1.95
Other pre-specifiedThe Number of Participants Who Achieved the Percentage of Response in at Least Moderate Migraine Days Baseline to Last 28 Days of Treatment
Time frame:
From baseline to month 3 of the treatment period.
Reported as:
Count of participants · Participants
The Number of Participants Who Achieved the Percentage of Response in at Least Moderate Migraine Days Baseline to Last 28 Days of Treatment
ParticipantsLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
≥50%42
≥75%41
≥90%31
100%31
Other pre-specifiedMean Severe Headache Days Change From Baseline to Last 28 Days of Treatment
Time frame:
From baseline to month 3 of the treatment period.
Reported as:
Mean · days
Mean Severe Headache Days Change From Baseline to Last 28 Days of Treatment
daysLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Mean monthly severe headaches days at baseline4.83 ± 1.724.33 ± 2.88
Mean severe headache days in the last 28 days of the treatment period2.67 ± 3.932.5 ± 3.02
The change in severe headache days from baseline to the last 28 days of the treatment period-2.17 ± 2.79-1.83 ± 3.87
Statistical analysis
  • Low-Dose Naltrexone and Acetaminophen Combination vs Placebo · Chi-squared · p = 0.8649 · Risk difference (rd): 0.34

Adverse events

Collected over One month follow-up after 3 months of treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low-Dose Naltrexone and Acetaminophen Combination0/6 (0%)0/6 (0%)4/6 (66.7%)
Placebo0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventLow-Dose Naltrexone and Acetaminophen CombinationPlacebo
Dry MouthGeneral disorders1/60/6
FatigueGeneral disorders1/61/6
Gastroesophageal RefluxGastrointestinal disorders1/60/6
Heavy BreathingGeneral disorders1/61/6
NauseaGeneral disorders1/60/6
PalpitationsGeneral disorders1/60/6
SomnolenceGeneral disorders1/61/6
VomitingGeneral disorders1/60/6

Baseline characteristics

Baseline analysis population included all treated participants (all enrolled participants who took the study drug).

Age, Categorical
Age, Categorical(Participants)Low-Dose Naltrexone and Acetaminophen CombinationPlaceboTotal
<=18 years000
Between 18 and 65 years6612
>=65 years000
Age, Continuous
Age, Continuous(years)Low-Dose Naltrexone and Acetaminophen CombinationPlaceboTotal
Mean41.5 ± 14.339 ± 10.440 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Low-Dose Naltrexone and Acetaminophen CombinationPlaceboTotal
Female4610
Male202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low-Dose Naltrexone and Acetaminophen CombinationPlaceboTotal
Hispanic or Latino448
Not Hispanic or Latino224
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low-Dose Naltrexone and Acetaminophen CombinationPlaceboTotal
Caucasian6511
African American011
Region of Enrollment
Region of Enrollment(participants)Low-Dose Naltrexone and Acetaminophen CombinationPlaceboTotal
United States6612
08

Study locations

1 site
  • Annette Toledano, M.D.
    North Miami, Florida 33181, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jul 2018, 11 months.

Results were first posted in Apr 2024, 5 years 8 months after primary completion.

Of 31 phase 2 interventional studies under Headache, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2017
First posted
Jun 21, 2017
StartActual
Aug 25, 2017
Primary completionActual
Jul 26, 2018
CompletionActual
Jul 28, 2018
Results first posted
Apr 10, 2024
Last update
Apr 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03194555
Lead sponsor
Allodynic Therapeutics, Inc
Responsible party
Sponsor
First posted
Jun 21, 2017
Start date
Aug 25, 2017
Primary completion
Jul 26, 2018
Completion
Jul 28, 2018
Results posted
Apr 10, 2024
Last update
Apr 10, 2024

Study contacts

Annette Toledano, M.D.
principal investigator · Allodynic Therapeutics, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Acetaminophen

Start the discussion